Phase I/II Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors, including Pancreatic Cancer
Summary
The purpose of this phase I/II study is to evaluate the safety and feasibility of CM24 in combination with nivolumab and nab-paclitaxel in patients with pancreatic cancer.
General Information
NCT#: NCT04731467
Study ID: FW-2020-1
Trial Phase: Phase I/II
Trial Sponsor: Famewave Ltd.
Therapies Used in This Trial: Nab-paclitaxel, Nivolumab, CM-24